This review summarises an interview between Associate Professor Judith Trotman, Concord Hospital, Sydney,
Australia and Professors Mathias Rummel and Martin Dreyling, two global leaders in the management of
low-grade lymphomas, which took place at the 14th International Conference on Malignant Lymphoma in June
2017, in Lugano, Switzerland.
Professors Rummel and Dreyling discussed recent findings of the StiL NHL1 and BRIGHT studies, and related these findings to their use of bendamustine for low-grade lymphomas in clinical practice.
Please login below to download this issue (PDF)